Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134929 | 0.88 | MKNK1 (0.47) | MKNK1MKNK2HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL6132468 | 0.85 | MKNK1 (0.48) | MKNK1MKNK2HRH3PDE4DPDE7A | |
| SCHEMBL6134521 | 0.84 | MKNK1 (0.45) | MKNK1MKNK2EPHX2KCNH2 | |
| SCHEMBL6134693 | 0.84 | MKNK1 (0.41) | MKNK1MKNK2HRH3 | |
| SCHEMBL6135285 | 0.83 | EPHX2 (0.52) | EPHX2HRH3KCNH2MEN1KMT2A | |
| SCHEMBL6133888 | 0.82 | HDAC3 (0.43) | MKNK1MKNK2HRH3KCNH2MEN1 | |
| SCHEMBL6134954 | 0.82 | MKNK1 (0.47) | MKNK1MKNK2KCNH2MEN1KMT2A | |
| SCHEMBL6134933 | 0.81 | HRH3 (0.48) | EPHX2HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL6135236 | 0.80 | MKNK1 (0.47) | MKNK1MKNK2PDE4DPDE7A | |
| SCHEMBL6132627 | 0.80 | MKNK1 (0.48) | MKNK1MKNK2PDE4DPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | MKNK1 2695/4885MKNK2 3220/4885EPHX2 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.